West Wealth Group LLC Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Posted by on Apr 2nd, 2023

West Wealth Group LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 4,496 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.

Several other hedge funds also recently modified their holdings of PFE. Saxon Interests Inc. raised its position in Pfizer by 12.9% during the 3rd quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 951 shares during the last quarter. Platte River Wealth Advisors LLC raised its position in Pfizer by 62.8% during the 3rd quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock worth $556,000 after purchasing an additional 4,905 shares during the last quarter. Accuvest Global Advisors raised its position in Pfizer by 16.6% during the 3rd quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock worth $569,000 after purchasing an additional 1,848 shares during the last quarter. Secure Asset Management LLC raised its position in Pfizer by 3.5% during the 4th quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after purchasing an additional 537 shares during the last quarter. Finally, Naples Global Advisors LLC raised its position in Pfizer by 0.9% during the 4th quarter. Naples Global Advisors LLC now owns 98,766 shares of the biopharmaceutical company’s stock worth $5,061,000 after purchasing an additional 887 shares during the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, major shareholder Pfizer Inc purchased 1,811,594 shares of the business’s stock in a transaction on Friday, March 17th. The stock was acquired at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the purchase, the insider now owns 5,952,263 shares of the company’s stock, valued at $16,428,245.88. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. UBS Group set a $45.00 price objective on Pfizer in a research report on Tuesday, March 14th. Berenberg Bank set a $40.00 price objective on Pfizer in a research report on Tuesday, February 7th. Credit Suisse Group lowered their price objective on Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research report on Wednesday, January 4th. Finally, Wells Fargo & Company lowered their price objective on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research report on Friday, March 17th. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $50.38.

Pfizer Price Performance

PFE stock opened at $40.80 on Friday. The company has a market capitalization of $230.29 billion, a P/E ratio of 7.45, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. Pfizer Inc. has a 52-week low of $39.23 and a 52-week high of $56.32. The business has a 50-day simple moving average of $41.98 and a two-hundred day simple moving average of $45.61.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.11. The business had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.08 EPS. Research analysts expect that Pfizer Inc. will post 3.3 EPS for the current fiscal year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.